Thomas Li

Correlation between patient and clinician assessments of depression severity in the PREVENT study

M. Keller, B. Dunlop, P. Ninan, 2010, Psychiatry Research.

Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75–225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study

M. Thase, M. Keller, B. Dunlop, 2008, International clinical psychopharmacology.

Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.

M. Trivedi, M. Thase, M. Keller, 2011, Journal of psychiatric research.

Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder.

M. Trivedi, M. Keller, B. Dunlop, 2011, Journal of psychiatric research.

Fremanezumab as Add‐On Treatment for Patients Treated With Other Migraine Preventive Medicines

D. Dodick, E. Aycardi, Ronghua Yang, 2017, Headache.

Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75–225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study

M. Thase, B. Dunlop, P. Ninan, 2008, International clinical psychopharmacology.

IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NE

A. Mouraux, R. Treede, I. Tracey, 2022, Trials.